B2B: Prostate Cancer Summary
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ADT | androgen deprivation therapy |
BCR | biochemical recurrence |
CI | confidence interval |
CT | computed tomography |
DRE | digital rectal examination |
EAU | European Association of Urology |
ePLND | extended pelvic lymph node dissection |
HR | high risk |
IR | intermediate risk |
LND | lymph node dissection |
LR | low risk |
LuPSMA | lutetium-177 PSMA-617 radionucleotide |
LUTS | lower urinary tract symptoms |
MFS | metastasis-free survival |
mpMRI | multiparametric magnetic resonance imaging |
MRI | magnetic resonance imaging |
OR | odds ratio |
OS | overall survival |
PCa | prostate cancer |
PET | positron emission tomography |
PI-RADS | Prostate Imaging-Reporting and Data System |
PLND | pelvic lymph node dissection |
PPUI | post-prostatectomy urinary incontinence |
PSA | prostate-specific antigen |
PSMA | prostate-specific membrane antigen |
RCT | randomized controlled trial |
RP | radical prostatectomy |
RT | radiotherapy |
SUVmax | maximum standardized uptake value |
TRUS | transrectal ultrasound |
References
- Martin, R.M.; Turner, E.L.; Young, G.J.; Metcalfe, C.; Walsh, E.I.; Lane, J.A.; Sterne, J.A.; Noble, S.; Holding, P.; Ben-Shlomo, Y.; et al. Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomized clinical trial. JAMA 2024, 331, 1460–1470. [Google Scholar] [CrossRef] [PubMed]
- Hugosson, J.; Roobol, M.J.; Månsson, M.; Tammela, T.L.; Zappa, M.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Carlsson, S.V.; Talala, K.M.; et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 2019, 76, 43–51. [Google Scholar] [CrossRef] [PubMed]
- Eldred-Evans, D.; Burak, P.; Connor, M.J.; Day, E.; Evans, M.; Fiorentino, F.; Gammon, M.; Hosking-Jervis, F.; Klimowska-Nassar, N.; McGuire, W.; et al. Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: The IP1-PROSTAGRAM study. JAMA Oncol. 2021, 7, 395–402. [Google Scholar] [CrossRef] [PubMed]
- Moore, C.M.; Frangou, E.; McCartan, N.; Santaolalla, A.; Kopcke, D.; Brembilla, G.; Hadley, J.; Giganti, F.; Marsden, T.; Van Hemelrijck, M.; et al. Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: A prospective cohort study. BMJ Oncol. 2023, 2, e000057. [Google Scholar] [CrossRef] [PubMed]
- Prostate Cancer UK. TRANSFORM Trial. Available online: https://prostatecanceruk.org/research/transform-trial (accessed on 14 November 2024).
- Borges, R.C.; Tobias-Machado, M.; Gabriotti, E.N.; Figueiredo, F.W.D.S.; Bezerra, C.A.; Glina, S. Post-radical prostatectomy urinary incontinence: Is there any discrepancy between medical reports and patients’ perceptions? BMC Urol. 2019, 19, 32. [Google Scholar] [CrossRef]
- Holm, H.V.; Fosså, S.D.; Hedlund, H.; Schultz, A.; Dahl, A.A. How should continence and incontinence after radical prostatectomy be evaluated? A prospective study of patient ratings and changes with time. J. Urol. 2014, 192, 1155–1161. [Google Scholar] [CrossRef] [PubMed]
- Ficarra, V.; Novara, G.; Rosen, R.C.; Artibani, W.; Carroll, P.R.; Costello, A.; Menon, M.; Montorsi, F.; Patel, V.R.; Stolzenburg, J.-U.; et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur. Urol. 2012, 62, 405–417. [Google Scholar] [CrossRef] [PubMed]
- Zattoni, F.; Artibani, W.; Patel, V.; Montorsi, F.; Porpiglia, F.; Hampton, L.J.; Rocco, B.; Dasgupta, P.; Hemal, A.K.; Mottrie, A.; et al. Technical innovations to optimize continence recovery after robotic assisted radical prostatectomy. Minerva Urol. Nefrol. 2019, 71, 324–338. [Google Scholar] [CrossRef]
- Tan, G.Y.; Jhaveri, J.K.; Tewari, A.K. Anatomic restoration technique: A biomechanics-based approach for early continence recovery after minimally invasive radical prostatectomy. Urology 2009, 74, 492–496. [Google Scholar] [CrossRef]
- Rocco, B.; Gregori, A.; Stener, S.; Santoro, L.; Bozzola, A.; Galli, S.; Knez, R.; Scieri, F.; Scaburri, A.; Gaboardi, F. Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. Eur. Urol. 2007, 51, 996–1003. [Google Scholar] [CrossRef] [PubMed]
- Porpiglia, F.; Bertolo, R.; Manfredi, M.; De Luca, S.; Checcucci, E.; Morra, I.; Passera, R.; Fiori, C. Total anatomical reconstruction during robot-assisted radical prostatectomy: Implications on early recovery of urinary continence. Eur. Urol. 2016, 69, 485–495. [Google Scholar] [CrossRef]
- Milios, J.E.; Ackland, T.R.; Green, D.J. Pelvic floor muscle training in radical prostatectomy: A randomized controlled trial of the impacts on pelvic floor muscle function and urinary incontinence. BMC Urol. 2019, 19, 116. [Google Scholar] [CrossRef] [PubMed]
- Schifano, N.; Capogrosso, P.; Tutolo, M.; Dehò, F.; Montorsi, F.; Salonia, A. How to prevent and manage post-prostatectomy incontinence: A review. World J. Mens. Health 2021, 39, 581–597. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.; Kim, K.B.; Lee, S.; Lee, S.W.; Kim, M.; Cho, S.Y.; Oh, S.-J.; Jeong, S.J. Urodynamic assessment of bladder and urethral function among men with lower urinary tract symptoms after radical prostatectomy: A comparison between men with and without urinary incontinence. Korean J. Urol. 2015, 56, 803–810. [Google Scholar] [CrossRef] [PubMed]
- Filocamo, M.T.; Marzi, V.L.; Del Popolo, G.; Cecconi, F.; Villari, D.; Marzocco, M.; Nicita, G. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur. Urol. 2007, 51, 1559–1564. [Google Scholar] [CrossRef]
- Fossati, N.; Willemse, P.-P.M.; Van den Broeck, T.; van den Bergh, R.C.; Yuan, C.Y.; Briers, E.; Bellmunt, J.; Bolla, M.; Cornford, P.; De Santis, M.; et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review. Eur. Urol. 2017, 72, 84–109. [Google Scholar] [CrossRef] [PubMed]
- Touijer, K.A.; Sjoberg, D.D.; Benfante, N.; Laudone, V.P.; Ehdaie, B.; Eastham, J.A.; Scardino, P.T.; Vickers, A. Limited versus extended pelvic lymph node dissection for prostate cancer: A randomized clinical trial. Eur. Urol. Oncol. 2021, 4, 532–539. [Google Scholar] [CrossRef] [PubMed]
- Briganti, A.; Chun, F.K.-H.; Salonia, A.; Suardi, N.; Gallina, A.; Da Pozzo, L.F.; Roscigno, M.; Zanni, G.; Valiquette, L.; Rigatti, P.; et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur. Urol. 2006, 50, 1006–1013. [Google Scholar] [CrossRef] [PubMed]
- Ploussard, G.; Briganti, A.; de la Taille, A.; Haese, A.; Heidenreich, A.; Menon, M.; Sulser, T.; Tewari, A.K.; Eastham, J.A. Pelvic lymph node dissection during robot-assisted radical prostatectomy: Efficacy, limitations, and complications-a systematic review of the literature. Eur. Urol. 2014, 65, 7–16. [Google Scholar] [CrossRef] [PubMed]
- Gupta, R.; Das, C.K.; Nair, S.S.; Pedraza-Bermeo, A.M.; Zahalka, A.H.; Kyprianou, N.; Bhardwaj, N.; Tewari, A.K. From foes to friends: Rethinking the role of lymph nodes in prostate cancer. Nat. Rev. Urol. 2024, 21, 687–700. [Google Scholar] [CrossRef]
- Stabile, A.; Pellegrino, A.; Mazzone, E.; Cannoletta, D.; de Angelis, M.; Barletta, F.; Scuderi, S.; Cucchiara, V.; Gandaglia, G.; Raggi, D.; et al. Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur. Urol. Oncol. 2022, 5, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Gandaglia, G.; Barletta, F.; Robesti, D.; Scuderi, S.; Rajwa, P.; Rivas, J.G.; Ibanez, L.; Soeterik, T.F.; Bianchi, L.; Afferi, L.; et al. Identification of the optimal candidates for nodal staging with extended pelvic lymph node dissection among prostate cancer patients who underwent preoperative prostate-specific membrane antigen positron emission tomography. External validation of the Memorial Sloan Kettering Cancer Center and Briganti nomograms and development of a novel tool. Eur. Urol. Oncol. 2023, 6, 543–552. [Google Scholar] [CrossRef] [PubMed]
- Arora, A.; Agarwal, A.; Pal, M.; Bakshi, G.; Menon, S.; Ajit, G.; Prakash, G. PD10-02 Using the negative predictive value and SUVmax of PSMA PET/CT for avoiding pelvic lymph node dissection with radical prostatectomy. J. Urol. 2023, 209 (Suppl. S4), e326. [Google Scholar] [CrossRef]
- Collamati, F.; Morganti, S.; van Oosterom, M.N.; Campana, L.; Ceci, F.; Luzzago, S.; Mancini-Terracciano, C.; Mirabelli, R.; Musi, G.; Nicolanti, F.; et al. First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: Defining optimal signal-to-background discrimination algorithm. Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3098–3108. [Google Scholar] [CrossRef]
- Quarta, L.; Mazzone, E.; Cannoletta, D.; Stabile, A.; Scuderi, S.; Barletta, F.; Cucchiara, V.; Nocera, L.; Pellegrino, A.; Robesti, D.; et al. Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: Updated results and ad interim analyses of a prospective phase II study. Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3789–3798. [Google Scholar] [CrossRef] [PubMed]
- Soeterik, T.F.; Wever, L.; Dijksman, L.M.; Frederix, G.W.; Van Melick, H.H.; Monninkhof, E.M.; Verkooijen, H.M.; Beerlage, H.P.; van Basten, J.-P.A.; Bergh, R.C.v.D. Clinical trial protocol for PSMA-SELECT: A Dutch national randomised study of prostate-specific membrane antigen positron emission tomography/computed tomography as a triage tool for pelvic lymph node dissection in patients undergoing radical prostatectomy. Eur. Urol. Focus. 2022, 8, 1198–1203. [Google Scholar] [CrossRef]
- Wu, H.; Xu, T.; Wang, X.; Yu, Y.-B.; Fan, Z.-Y.; Li, D.-X.; Luo, L.; Yang, X.-C.; Jiao, W.; Niu, H.-T. Diagnostic performance of 68Gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: A systematic review and meta-analysis. World J. Mens. Health 2020, 38, 208–219. [Google Scholar] [CrossRef] [PubMed]
- Van Damme, J.; Tombal, B.; Collette, L.; Van Nieuwenhove, S.; Pasoglou, V.; Gérard, T.; Jamar, F.; Lhommel, R.; Lecouvet, F.E. Comparison of 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) with diffusion sequences (DWI) in the staging of advanced prostate cancer. Cancers 2021, 13, 5286. [Google Scholar] [CrossRef] [PubMed]
- Perera, M.; Papa, N.; Roberts, M.; Williams, M.; Udovicich, C.; Vela, I.; Christidis, D.; Bolton, D.; Hofman, M.S.; Lawrentschuk, N.; et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis. Eur. Urol. 2020, 77, 403–417. [Google Scholar] [CrossRef] [PubMed]
- Mottet, N.; Van den Bergh, R.C.N.; Briers, E.; Cornford, P.; De Santis, M.; Fanti, S.; Gillessen, S.; Grummet, J.; Henry, A.M.; Lam, T.B. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 2021, 79, 243–262. [Google Scholar] [CrossRef]
- European Association of Urology. Prostate Cancer. Available online: https://uroweb.org/guidelines/prostate-cancer (accessed on 14 November 2024).
- Hope, T.A.; Eiber, M.; Armstrong, W.R.; Juarez, R.; Murthy, V.; Lawhn-Heath, C.; Behr, S.C.; Zhang, L.; Barbato, F.; Ceci, F.; et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021, 7, 1635–1642. [Google Scholar] [CrossRef] [PubMed]
- Pienta, K.J.; Gorin, M.A.; Rowe, S.P.; Carroll, P.R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.A.; Alva, A.S.; Patnaik, A.; et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J. Urol. 2021, 206, 52–61. [Google Scholar] [CrossRef]
- Mattei, A.; Fuechsel, F.G.; Dhar, N.B.; Warncke, S.H.; Thalmann, G.N.; Krause, T.; Studer, U.E. The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study. Eur. Urol. 2008, 53, 118–125. [Google Scholar] [CrossRef] [PubMed]
- Jansen, B.H.E.; Bodar, Y.J.L.; Zwezerijnen, G.J.C.; Meijer, D.; Van Der Voorn, J.P.; Nieuwenhuijzen, J.A.; Wondergem, M.; Roeleveld, T.A.; Boellaard, R.; Hoekstra, O.S.; et al. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer: The SALT trial. Eur. J. Nucl. Med. Mol. Imaging 2020, 48, 509. [Google Scholar] [CrossRef] [PubMed]
- Lodeta, B.; Baric, H.; Hatz, D.; Jozipovic, D.; Augustin, H. Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: Comparison of five nomograms. BMC Urol. 2023, 23, 190. [Google Scholar] [CrossRef]
- Meijer, D.; van Leeuwen, P.J.; Roberts, M.J.; Siriwardana, A.R.; Morton, A.; Yaxley, J.W.; Samaratunga, H.; Emmett, L.; van de Ven, P.M.; van der Poel, H.G.; et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An international multicenter study. Eur. Urol. 2021, 80, 234–242. [Google Scholar] [CrossRef]
- Perez-Ardavin, J.; Martinez-Sarmiento, M.; Monserrat-Monfort, J.J.; Vera-Pinto, V.; Sopena-Novales, P.; Bello-Arqués, P.; Boronat-Tormo, F.; Vera-Donoso, C.D. The sentinel node with technetium-99m for prostate cancer. A safe and mature new gold standard? Q. J. Nucl. Med. Mol. Imaging 2023, 67, 287–293. [Google Scholar] [CrossRef] [PubMed]
- Sabbagh, A.; Washington, S.L.; Tilki, D.; Hong, J.C.; Feng, J.; Valdes, G.; Chen, M.-H.; Wu, J.; Huland, H.; Graefen, M.; et al. Development and external validation of a machine learning model for prediction of lymph node metastasis in patients with prostate cancer. Eur. Urol. Oncol. 2023, 6, 501–507. [Google Scholar] [CrossRef] [PubMed]
- Xie, W.; Regan, M.M.; Buyse, M.; Halabi, S.; Kantoff, P.W.; Sartor, O.; Soule, H.; Clarke, N.W.; Collette, L.; Dignam, J.J.; et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol. 2017, 35, 3097–3104. [Google Scholar] [CrossRef]
- Gharzai, L.A.; Jiang, R.; Wallington, D.; Jones, G.; Birer, S.; Jairath, N.; Jaworski, E.M.; McFarlane, M.R.; Mahal, B.A.; Nguyen, P.L.; et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: An aggregate meta-analysis. Lancet Oncol. 2021, 22, 402–410. [Google Scholar] [CrossRef] [PubMed]
- Pound, C.R.; Partin, A.W.; Eisenberger, M.A.; Chan, D.W.; Pearson, J.D.; Walsh, P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281, 1591–1597. [Google Scholar] [CrossRef] [PubMed]
- Tilki, D.; Preisser, F.; Graefen, M.; Huland, H.; Pompe, R.S. External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur. Urol. 2019, 75, 896–900. [Google Scholar] [CrossRef]
- Albisinni, S.; Artigas, C.; Aoun, F.; Biaou, I.; Grosman, J.; Gil, T.; Hawaux, E.; Limani, K.; Otte, F.; Peltier, A.; et al. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017, 120, 197–203. [Google Scholar] [CrossRef]
- Adebahr, S.; Althaus, A.; Scharl, S.; Strouthos, I.; Farolfi, A.; Serani, F.; Lanzafame, H.; Trapp, C.; Koerber, S.A.; Peeken, J.C.; et al. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2023, 51, 558. [Google Scholar] [CrossRef] [PubMed]
- Jani, A.B.; Schreibmann, E.; Goyal, S.; Halkar, R.; Hershatter, B.; Rossi, P.J.; Shelton, J.W.; Patel, P.R.; Xu, K.M.; Goodman, M.; et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): A single centre, open-label, phase 2/3 randomised controlled trial. Lancet 2021, 397, 1895–1904. [Google Scholar] [CrossRef] [PubMed]
- Abiodun-Ojo, O.A.; Jani, A.B.; Akintayo, A.A.; Akin-Akintayo, O.O.; Odewole, O.A.; Tade, F.I.; Joshi, S.S.; Master, V.A.; Fielder, B.; Halkar, R.K.; et al. Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-fluciclovine PET/CT guidance. J. Nucl. Med. 2021, 62, 1089–1096. [Google Scholar] [CrossRef] [PubMed]
- Parker, C.C.; Kynaston, H.; Cook, A.D.; Clarke, N.W.; Catton, C.N.; Cross, W.R.; Petersen, P.M.; Persad, R.A.; Pugh, C.A.; Saad, F.; et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: A comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet 2024, 403, 2416–2425. [Google Scholar] [CrossRef]
- Freedland, S.J.; Luz, M.d.A.; De Giorgi, U.; Gleave, M.; Gotto, G.T.; Pieczonka, C.M.; Haas, G.P.; Kim, C.-S.; Ramirez-Backhaus, M.; Rannikko, A.; et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 2023, 389, 1453–1465. [Google Scholar] [CrossRef] [PubMed]
- Hofman, M.S.; Violet, J.; Hicks, R.J.; Ferdinandus, J.; Thang, S.P.; Akhurst, T.; Iravani, A.; Kong, G.; Kumar, A.R.; Murphy, D.G.; et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 825–833. [Google Scholar] [CrossRef] [PubMed]
- Hofman, M.S.; Emmett, L.; Sandhu, S.; Iravani, A.; Joshua, A.M.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Ng, S.; et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet 2021, 397, 797–804. [Google Scholar] [CrossRef] [PubMed]
- Sartor, A.O.; Morris, M.J.; Chi, K.N.; De Bono, J.S.; Shore, N.D.; Crosby, M.; Kreisl, T.N.; Fizazi, K. PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2022, 40 (Suppl. S6), TPS211. [Google Scholar] [CrossRef]
- Tosco, L.; Briganti, A.; D’amico, A.V.; Eastham, J.; Eisenberger, M.; Gleave, M.; Haustermans, K.; Logothetis, C.J.; Saad, F.; Sweeney, C.; et al. Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur. Urol. 2019, 75, 44–60. [Google Scholar] [CrossRef] [PubMed]
- Eapen, R.S.; Buteau, J.P.; Jackson, P.; Mitchell, C.; Oon, S.F.; Alghazo, O.; McIntosh, L.; Dhiantravan, N.; Scalzo, M.J.; O’Brien, J.; et al. Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): A single-centre, single-arm, phase 1/2 study. Eur. Urol. 2024, 85, 217–226. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Société Internationale d’Urologie. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Prakash, G.; Moore, C.M.; Bladou, F.; Secco, S.; Addla, S.; Maitre, P.; Rajappa, S.; Woo, H.; Bolton, D.; Black, P.C.; et al. B2B: Prostate Cancer Summary. Soc. Int. Urol. J. 2025, 6, 16. https://doi.org/10.3390/siuj6010016
Prakash G, Moore CM, Bladou F, Secco S, Addla S, Maitre P, Rajappa S, Woo H, Bolton D, Black PC, et al. B2B: Prostate Cancer Summary. Société Internationale d’Urologie Journal. 2025; 6(1):16. https://doi.org/10.3390/siuj6010016
Chicago/Turabian StylePrakash, Gagan, Caroline M. Moore, Franck Bladou, Silvia Secco, Sanjai Addla, Priyamvada Maitre, Senthil Rajappa, Henry Woo, Damien Bolton, Peter C. Black, and et al. 2025. "B2B: Prostate Cancer Summary" Société Internationale d’Urologie Journal 6, no. 1: 16. https://doi.org/10.3390/siuj6010016
APA StylePrakash, G., Moore, C. M., Bladou, F., Secco, S., Addla, S., Maitre, P., Rajappa, S., Woo, H., Bolton, D., Black, P. C., & Tanguay, S. (2025). B2B: Prostate Cancer Summary. Société Internationale d’Urologie Journal, 6(1), 16. https://doi.org/10.3390/siuj6010016